Compugen Management
Management criteria checks 3/4
Compugen's CEO is Anat Cohen-Dayag, appointed in Jun 2009, has a tenure of 15.42 years. total yearly compensation is $1.46M, comprised of 32.7% salary and 67.3% bonuses, including company stock and options. directly owns 0.063% of the company’s shares, worth $95.97K. The average tenure of the management team and the board of directors is 5 years and 7.4 years respectively.
Key information
Anat Cohen-Dayag
Chief executive officer
US$1.5m
Total compensation
| CEO salary percentage | 32.7% |
| CEO tenure | 15.4yrs |
| CEO ownership | 0.06% |
| Management average tenure | 5yrs |
| Board average tenure | 7.4yrs |
Recent management updates
Recent updates
Investors Aren't Buying Compugen Ltd.'s (NASDAQ:CGEN) Revenues
Aug 22
Analysts Have Been Trimming Their Compugen Ltd. (NASDAQ:CGEN) Price Target After Its Latest Report
May 22Why Investors Shouldn't Be Surprised By Compugen Ltd.'s (NASDAQ:CGEN) 25% Share Price Plunge
May 01Is Compugen Ltd. (NASDAQ:CGEN) Trading At A 36% Discount?
Apr 05Compugen Ltd.'s (NASDAQ:CGEN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Mar 08Compugen (NASDAQ:CGEN) Is In A Good Position To Deliver On Growth Plans
Feb 17Will Compugen (NASDAQ:CGEN) Spend Its Cash Wisely?
Oct 10Is Compugen (NASDAQ:CGEN) In A Good Position To Invest In Growth?
Jun 22Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 04Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Sep 21Compugen appoints Alberto Sessa as CFO
Sep 12Compugen gets Japanese patent for COM701, anti-PVRIG antibodies
Aug 24Compugen Q2 2022 Earnings Preview
Aug 03Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Jun 23Companies Like Compugen (NASDAQ:CGEN) Are In A Position To Invest In Growth
Mar 02Here's Why We're Not Too Worried About Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 04Shareholders Will Probably Not Have Any Issues With Compugen Ltd.'s (NASDAQ:CGEN) CEO Compensation
Aug 27Companies Like Compugen (NASDAQ:CGEN) Can Afford To Invest In Growth
Jun 28Compugen gains on takeover speculation after iTeos Therapeutics deal
Jun 14Compugen reports updated COM701 data from Phase 1 study at ASCO21
Jun 08Compugen's COM902 demonstrates potential benefit in cancer
Apr 27Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Mar 15Are Institutions Heavily Invested In Compugen Ltd.'s (NASDAQ:CGEN) Shares?
Feb 08
A Look At The Fair Value Of Compugen Ltd. (NASDAQ:CGEN)
Jan 04Compugen earns $2M milestone under antibody development deal with AstraZeneca
Dec 23Here's Why We're Not At All Concerned With Compugen's (NASDAQ:CGEN) Cash Burn Situation
Nov 30Compugen Ltd. 2020 Q3 - Results - Earnings Call Presentation
Nov 08Compugen: Speculative Play For Immuno-Oncology Exposure
Nov 07Compugen Q3 Earnings Preview
Nov 04CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$10m |
| Mar 31 2024 | n/a | n/a | -US$17m |
| Dec 31 2023 | US$1m | US$479k | -US$19m |
| Sep 30 2023 | n/a | n/a | -US$32m |
| Jun 30 2023 | n/a | n/a | -US$33m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$479k | -US$34m |
| Sep 30 2022 | n/a | n/a | -US$39m |
| Jun 30 2022 | n/a | n/a | -US$34m |
| Mar 31 2022 | n/a | n/a | -US$34m |
| Dec 31 2021 | US$1m | US$498k | -US$34m |
| Sep 30 2021 | n/a | n/a | -US$34m |
| Jun 30 2021 | n/a | n/a | -US$36m |
| Mar 31 2021 | n/a | n/a | -US$32m |
| Dec 31 2020 | US$1m | US$453k | -US$30m |
| Sep 30 2020 | n/a | n/a | -US$28m |
| Jun 30 2020 | n/a | n/a | -US$26m |
| Mar 31 2020 | n/a | n/a | -US$26m |
| Dec 31 2019 | US$941k | US$395k | -US$27m |
| Sep 30 2019 | n/a | n/a | -US$30m |
| Jun 30 2019 | n/a | n/a | -US$27m |
| Mar 31 2019 | n/a | n/a | -US$31m |
| Dec 31 2018 | US$854k | US$391k | -US$23m |
| Sep 30 2018 | n/a | n/a | -US$23m |
| Jun 30 2018 | n/a | n/a | -US$29m |
| Mar 31 2018 | n/a | n/a | -US$28m |
| Dec 31 2017 | US$740k | US$392k | -US$37m |
Compensation vs Market: Anat's total compensation ($USD1.46M) is about average for companies of similar size in the US market ($USD1.48M).
Compensation vs Earnings: Anat's compensation has increased whilst the company is unprofitable.
CEO
Anat Cohen-Dayag (57 yo)
15.4yrs
Tenure
US$1,464,448
Compensation
Dr. Anat Cohen-Dayag, Ph D., served as an Independent Director at Gamida Cell Ltd since January 28, 2022 until March 2023. She serves as Director at has been Chief Executive Officer and President at Compug...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 15.4yrs | US$1.46m | 0.063% $ 96.0k | |
| Chief Scientific Officer | 4.7yrs | US$540.64k | no data | |
| Senior Vice President of Technology Innovation | 6.8yrs | US$532.26k | no data | |
| Vice President of Preclinical Development | 3.6yrs | US$570.40k | no data | |
| Chief Financial Officer | less than a year | no data | no data | |
| Head of Investor Relations & Corporate Communications | no data | no data | no data | |
| General Counsel & Corporate Secretary | 5.8yrs | no data | no data | |
| Vice President of Human Resources | 17.8yrs | no data | no data | |
| Senior VP & Senior Advisor of Data and Informatics Solutions | 5yrs | no data | no data | |
| Vice President Research and Discovery | no data | no data | no data | |
| Chief Medical Officer | less than a year | no data | no data |
5.0yrs
Average Tenure
53yo
Average Age
Experienced Management: CGEN's management team is seasoned and experienced (5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO, President & Director | 10.8yrs | US$1.46m | 0.063% $ 96.0k | |
| Member of Scientific Advisory Board | 4.2yrs | no data | no data | |
| Independent Director | 6.4yrs | no data | no data | |
| Member of Scientific Advisory Board | 11.3yrs | no data | no data | |
| Independent Director | 6.4yrs | no data | no data | |
| Independent Chairman of the Board | 7.1yrs | no data | no data | |
| Independent Director | 6.4yrs | no data | no data | |
| Chairman of Scientific Advisory Board | 10.8yrs | no data | no data | |
| Member of Scientific Advisory Board | 11.3yrs | no data | no data | |
| Independent Director | 5.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 11.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 7.7yrs | no data | no data |
7.4yrs
Average Tenure
58yo
Average Age
Experienced Board: CGEN's board of directors are considered experienced (7.4 years average tenure).